Title: Whole-Body Biodistribution and Radiation Dosimetry of F-18-GE067: A Radioligand for In Vivo Brain Amyloid Imaging
Authors: Koole, Michel ×
Lewis, Dewi M
Buckley, Christopher
Nelissen, Natalie
Vandenbulcke, Mathieu
Brooks, David J
Vandenberghe, Rik
Van Laere, Koen #
Issue Date: May-2009
Publisher: Society of Nuclear Medicine
Series Title: Journal of Nuclear Medicine vol:50 issue:5 pages:818-822
Abstract: We have characterized the biodistribution and dosimetry of F-18-3'-F-6-OH-BTA1 (F-18-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of F-18-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. F-18-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 mu Gy/MBq, respectively). The mean effective dose was 33.8 +/- 3.4 mu Sv/MBq, a dose comparable to that of many other F-18-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of F-18-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.
ISSN: 0161-5505
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Nuclear Medicine & Molecular Imaging
Research Group Psychiatry
Research Group Experimental Neurology
Laboratory for Cognitive Neurology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
jnm2009a.pdf Published 879KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science